Literature DB >> 4796593

Trimethoprim-sulfamethoxazole in brucellosis.

G K Daikos, N Papapolyzos, N Marketos, S Mochlas, S Kastanakis, E Papasteriadis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4796593     DOI： 10.1093/infdis/128.supplement_3.s731

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

Review 1.  Antibacterial drugs today. I.

Authors:  A P Ball; J A Gray; J M Murdoch
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Co-trimoxazole in chronic brucellosis: a two-year follow-up study.

Authors:  P A Kontoyannis; S E Papapoulos; A A Mortoglou
Journal:  Br Med J       Date:  1975-05-31

3.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 4.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

5.  Brucellosis: difficulties in diagnosis and a report on 38 cases.

Authors:  Y Samra; Y Shaked; M Hertz; G Altman
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

6.  Brucellosis treated with rifampicin.

Authors:  J Llorens-Terol; R M Busquets
Journal:  Arch Dis Child       Date:  1980-06       Impact factor: 3.791

Review 7.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.